查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566751

肿瘤和癌症药物市场：按药物类别和适应症分类：2024-2033 年全球机会分析和产业预测

Oncology-Cancer Drugs Market By Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy , Hormonal Therapy), By Indication : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球肿瘤和癌症治疗市场价值为1,670亿美元，预计2024年至2033年复合年增长率为7.2%，到2033年达到3,352亿美元。

肿瘤/癌症药物包括用于诊断、治疗和管理各种类型癌症的专用药物。这些药物针对癌细胞或抑制癌症生长和扩散的过程。它包括广泛的治疗药物方法，从传统化疗到免疫疗法和精准医学等标靶治疗。

全球肿瘤学和癌症治疗市场受到人口老化、生活方式变化以及环境暴露导致的全球癌症发病率上升的推动，从而推动了对创新疗法的需求。患者数量的增加凸显了需要继续进行研究和开发工作，以解决不同的癌症类型和未满足的医疗需求。此外，科学技术领域的进步，特别是分子生物学、基因组学和免疫治疗等领域的进步，正在推动抗癌药物开发的重大进展。专注于驱动癌症进展的特定分子异常的精准医学策略的兴起变得越来越突出。结果是更强大、危害更小的治疗方法，推动了肿瘤学和癌症药物市场的成长。

然而，肿瘤/癌症药物的开发成本高昂，往往需要大量的临床前研究、临床试验投资，且监管核准有限；然而，与新疗法和药物相关的监管核准预计将为市场参与企业提供一些机会。例如，2023 年 10 月，美国食品药物管理局(FDA) 在夏季核准了多种针对各种癌症的新疗法。 7月，FDA核准了Jemperli（dostarlimab）治疗子宫内膜癌的新适应症。

细分概述

肿瘤/癌症药物市场按药物类别、适应症和地区细分。依药物类别分为化疗、标靶治疗、免疫治疗（生技药品）和荷尔蒙疗法。依适应症分为肺癌、胃癌、大肠直肠癌、乳癌、摄护腺癌、肝癌、食道癌、子宫颈癌、肾臟癌、膀胱癌等癌症。按地区划分，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

依药物类别划分，2023年标靶治疗领域占最大市场占有率。

有迹象表明，乳癌细分市场在 2023 年占据了最高的市场份额。

按地区划分，北美在 2023 年占据肿瘤学和癌症治疗市场的主导地位。

竞争场景

该报告可以定制。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章肿瘤/癌症药物市场：依药物类别

  • 市场概况
  • 化疗
  • 标靶治疗
  • 免疫疗法（生物疗法）
  • 荷尔蒙疗法

第五章肿瘤/癌症药物市场：依适应症分类

  • 市场概况
  • 肺癌
  • 胃癌
  • 大肠直肠癌
  • 乳癌
  • 摄护腺癌
  • 肝癌
  • 食道癌
  • 子宫颈癌
  • 肾癌
  • 膀胱癌
  • 其他癌症

第六章肿瘤/癌症药物市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国肿瘤/癌症药物市场
    • 加拿大肿瘤学/癌症药物市场
    • 墨西哥肿瘤和癌症药物市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国肿瘤学/癌症药物市场
    • 法国肿瘤/癌症药物市场
    • 英国肿瘤学/癌症药物市场
    • 义大利肿瘤/癌症药物市场
    • 西班牙肿瘤学/癌症药物市场
    • 其他欧洲肿瘤/癌症药物市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国肿瘤/癌症药物市场
    • 日本肿瘤/癌症治疗药物市场
    • 印度肿瘤/癌症药物市场
    • 澳洲肿瘤学/癌症药物市场
    • 韩国肿瘤/癌症药物市场
    • 其他亚太肿瘤学和癌症药物市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西肿瘤学/癌症药物市场
    • 南非肿瘤学/癌症药物市场
    • 沙乌地阿拉伯的肿瘤和癌症药物市场
    • 拉丁美洲、中东和非洲的其他肿瘤和癌症药物市场

第七章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第八章 公司简介

  • AbbVie Inc.
  • Amgen
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson And Johnson
  • Merck And Co., Inc.
  • Novartis AG
  • Pfizer Inc.
简介目录
Product Code: A00042

The global oncology-cancer drugs market was valued at $167.0 billion in 2023, and is projected to reach $335.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

The oncology/cancer drugs encompass pharmaceuticals specifically designed to diagnose, treat, and manage various types of cancer. These drugs target cancerous cells or interfere with processes involved in cancer growth and spread. It includes a wide array of therapeutic approaches, ranging from traditional chemotherapy to more targeted therapies like immunotherapy and precision medicine.

The global oncology-cancer drugs market is driven by rise in incidence of cancer globally due to aging population, lifestyle changes, and environmental exposures, which drives the demand for innovative therapies. This growing patient population highlights the need for continuous R&D efforts to address diverse cancer types and unmet medical needs. Furthermore, progress in the field of science and technology, specifically in disciplines such as molecular biology, genomics, and immunotherapy, are propelling substantial advancements in the development of cancer drugs. The rise of precision medicine strategies, which focus on specific molecular abnormalities that fuel cancer progression, is becoming increasingly prominent. This has resulted in the creation of more potent and less harmful therapies, fueling growth in the oncology drugs market.

However, high development costs of oncology drugs are extensive and costly, often requiring significant investments in preclinical studies, clinical trials, and regulatory approvals which limit the adoption of cancer drugs. Nevertheless, approval from regulatory authorities associated with new treatments and drugs is expected to create several opportunities for the market players. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved several new treatments for a range of cancers over the summer. In July, the FDA approved a new indication for Jemperli (dostarlimab) in endometrial cancer.

Segmentation Overview

The oncology-cancer drugs market is segmented into drug class type, indication, and region. Depending on drug class type, the market is categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. According to indication, it is divided into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

Depending on drug class type, the targeted therapy segment held the largest market share in 2023.

By indication, the breast cancer segment accounted for the highest share in the market in 2023.

Region wise, North America dominated the oncology-cancer drugs market in 2023.

Competitive Scenario

The major players operating in the oncology/cancer drugs market include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. Other players in oncology/cancer drugs market includes Bayer AG, Regeneron Pharmaceuticals Inc., and Eli Lilly and Company. These players have adopted several strategies, including partnerships, collaborations, and R&D to maintain their position in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • AbbVie Inc.
    • Amgen
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Class
  • 4.2. Chemotherapy
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Targeted Therapy
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Immunotherapy (Biologic Therapy)
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Hormonal Therapy
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Lung Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Stomach Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Colorectal Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Breast Cancer
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Prostate Cancer
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Liver Cancer
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country
  • 5.8. Esophagus Cancer
    • 5.8.1. Key Market Trends, Growth Factors and Opportunities
    • 5.8.2. Market Size and Forecast, By Region
    • 5.8.3. Market Share Analysis, By Country
  • 5.9. Cervical Cancer
    • 5.9.1. Key Market Trends, Growth Factors and Opportunities
    • 5.9.2. Market Size and Forecast, By Region
    • 5.9.3. Market Share Analysis, By Country
  • 5.10. Kidney Cancer
    • 5.10.1. Key Market Trends, Growth Factors and Opportunities
    • 5.10.2. Market Size and Forecast, By Region
    • 5.10.3. Market Share Analysis, By Country
  • 5.11. Bladder Cancer
    • 5.11.1. Key Market Trends, Growth Factors and Opportunities
    • 5.11.2. Market Size and Forecast, By Region
    • 5.11.3. Market Share Analysis, By Country
  • 5.12. Other Cancers
    • 5.12.1. Key Market Trends, Growth Factors and Opportunities
    • 5.12.2. Market Size and Forecast, By Region
    • 5.12.3. Market Share Analysis, By Country

CHAPTER 6: ONCOLOGY-CANCER DRUGS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Drug Class
    • 6.2.3. Market Size and Forecast, By Indication
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Oncology-Cancer Drugs Market
      • 6.2.5.1. Market Size and Forecast, By Drug Class
      • 6.2.5.2. Market Size and Forecast, By Indication
    • 6.2.6. Canada Oncology-Cancer Drugs Market
      • 6.2.6.1. Market Size and Forecast, By Drug Class
      • 6.2.6.2. Market Size and Forecast, By Indication
    • 6.2.7. Mexico Oncology-Cancer Drugs Market
      • 6.2.7.1. Market Size and Forecast, By Drug Class
      • 6.2.7.2. Market Size and Forecast, By Indication
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Drug Class
    • 6.3.3. Market Size and Forecast, By Indication
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Oncology-Cancer Drugs Market
      • 6.3.5.1. Market Size and Forecast, By Drug Class
      • 6.3.5.2. Market Size and Forecast, By Indication
    • 6.3.6. France Oncology-Cancer Drugs Market
      • 6.3.6.1. Market Size and Forecast, By Drug Class
      • 6.3.6.2. Market Size and Forecast, By Indication
    • 6.3.7. UK Oncology-Cancer Drugs Market
      • 6.3.7.1. Market Size and Forecast, By Drug Class
      • 6.3.7.2. Market Size and Forecast, By Indication
    • 6.3.8. Italy Oncology-Cancer Drugs Market
      • 6.3.8.1. Market Size and Forecast, By Drug Class
      • 6.3.8.2. Market Size and Forecast, By Indication
    • 6.3.9. Spain Oncology-Cancer Drugs Market
      • 6.3.9.1. Market Size and Forecast, By Drug Class
      • 6.3.9.2. Market Size and Forecast, By Indication
    • 6.3.10. Rest of Europe Oncology-Cancer Drugs Market
      • 6.3.10.1. Market Size and Forecast, By Drug Class
      • 6.3.10.2. Market Size and Forecast, By Indication
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Drug Class
    • 6.4.3. Market Size and Forecast, By Indication
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Oncology-Cancer Drugs Market
      • 6.4.5.1. Market Size and Forecast, By Drug Class
      • 6.4.5.2. Market Size and Forecast, By Indication
    • 6.4.6. Japan Oncology-Cancer Drugs Market
      • 6.4.6.1. Market Size and Forecast, By Drug Class
      • 6.4.6.2. Market Size and Forecast, By Indication
    • 6.4.7. India Oncology-Cancer Drugs Market
      • 6.4.7.1. Market Size and Forecast, By Drug Class
      • 6.4.7.2. Market Size and Forecast, By Indication
    • 6.4.8. Australia Oncology-Cancer Drugs Market
      • 6.4.8.1. Market Size and Forecast, By Drug Class
      • 6.4.8.2. Market Size and Forecast, By Indication
    • 6.4.9. South Korea Oncology-Cancer Drugs Market
      • 6.4.9.1. Market Size and Forecast, By Drug Class
      • 6.4.9.2. Market Size and Forecast, By Indication
    • 6.4.10. Rest of Asia-Pacific Oncology-Cancer Drugs Market
      • 6.4.10.1. Market Size and Forecast, By Drug Class
      • 6.4.10.2. Market Size and Forecast, By Indication
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Drug Class
    • 6.5.3. Market Size and Forecast, By Indication
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Oncology-Cancer Drugs Market
      • 6.5.5.1. Market Size and Forecast, By Drug Class
      • 6.5.5.2. Market Size and Forecast, By Indication
    • 6.5.6. South Africa Oncology-Cancer Drugs Market
      • 6.5.6.1. Market Size and Forecast, By Drug Class
      • 6.5.6.2. Market Size and Forecast, By Indication
    • 6.5.7. Saudi Arabia Oncology-Cancer Drugs Market
      • 6.5.7.1. Market Size and Forecast, By Drug Class
      • 6.5.7.2. Market Size and Forecast, By Indication
    • 6.5.8. Rest of LAMEA Oncology-Cancer Drugs Market
      • 6.5.8.1. Market Size and Forecast, By Drug Class
      • 6.5.8.2. Market Size and Forecast, By Indication

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. AbbVie Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Amgen
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Astellas Pharma Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. AstraZeneca Plc
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Bristol-Myers Squibb Company
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. F. Hoffmann-La Roche Ltd.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Johnson And Johnson
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Merck And Co., Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Novartis AG
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Pfizer Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments